Carisbamate not checked
SK Life Science, Inc. · YKP509
FollowEvery change as it happens, and a Monday email
Trials
1 active
4 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]). Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\]).”In the company’s words, NCT05219617 on ClinicalTrials.gov
- Tested for
- Seizures, Lennox Gastaut Syndrome
- Main trialPhase 3
- “The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).”In the company’s words, NCT05219617 on ClinicalTrials.gov
- Other names
- YKP509
Other drugs for Seizures
- BHV-7000Biohaven · Phase 2/3
- ElsunersenPraxis Precision Medicines · Phase 3
- LP352Longboard Pharmaceuticals · Phase 3
- EverolimusNovartis Pharmaceuticals · Phase 3
- Clemizole HClEpygenix · Phase 3
- ZX008Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. · Phase 3
Coming up1
- Feb 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Feb 2027 | Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | |
| Phase 1Completed | 6 Oct 2021 | Bioavailability and Food Effect Study of 3 Types of Carisbamate | |
| Phase 1Completed | 23 May 2022 | Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome | |
| Phase 1Completed | 14 Dec 2022 | Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026